Elissa R Weitzman1,2,3, Kara M Magane4, Lauren E Wisk4,3, Joseph Allario5, Elizabeth Harstad3,5, Sharon Levy3,5. 1. Divisions of Adolescent and Young Adult Medicine and elissa.weitzman@childrens.harvard.edu. 2. Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts; and. 3. Department of Pediatrics, Harvard Medical School, Harvard University, Boston, Massachusetts. 4. Divisions of Adolescent and Young Adult Medicine and. 5. Developmental Medicine, and.
Abstract
BACKGROUND AND OBJECTIVES: Despite their medical vulnerability, youth with chronic medical conditions (YCMCs) drink at levels commensurate with healthy youth. However, information about the prevalence of alcohol use among YCMCs who take alcohol-interactive (AI) medications is scant. To address gaps and inform interventions, we quantified simultaneous exposure to alcohol use and AI medications among YCMCs, hypothesizing that AI exposure would be associated with lower alcohol consumption and mediated by perceptions of alcohol-medication interference. METHODS: Adolescents with type 1 diabetes, juvenile idiopathic arthritis, moderate persistent asthma, cystic fibrosis, attention-deficit/hyperactivity disorder, or inflammatory bowel disease completed an electronic survey. We measured the prevalence of exposure to AI medications and the associations with past-year alcohol use as well as binge drinking and total consumption volume in the past 3 months using multivariate regression to estimate the odds of alcohol use given AI medication exposure and perceptions of interference. RESULTS: Of 396 youth, 86.4% were on AI medications, of whom, 35.4% reported past-year alcohol use (46.3% among those who were not on AI medications). AI medication use was associated with 43% lower odds of past-year alcohol use (adjusted odds ratio: 0.57; 95% confidence interval: 0.39-0.85) and lower total consumption (β = -.43; SE = 0.11; P < .001). Perceptions of alcohol-medication interference partially mediated the relationship between AI medication exposure and past-year alcohol use (Sobel test P = .05). CONCLUSIONS: Many YCMCs reported using alcohol; however, drinking was less likely among those who were taking AI medications. Perceptions about alcohol-medication interference mediated the association between drinking and AI medication exposure, suggesting the potential salience of interventions that emphasize alcohol-related risks.
BACKGROUND AND OBJECTIVES: Despite their medical vulnerability, youth with chronic medical conditions (YCMCs) drink at levels commensurate with healthy youth. However, information about the prevalence of alcohol use among YCMCs who take alcohol-interactive (AI) medications is scant. To address gaps and inform interventions, we quantified simultaneous exposure to alcohol use and AI medications among YCMCs, hypothesizing that AI exposure would be associated with lower alcohol consumption and mediated by perceptions of alcohol-medication interference. METHODS: Adolescents with type 1 diabetes, juvenile idiopathic arthritis, moderate persistent asthma, cystic fibrosis, attention-deficit/hyperactivity disorder, or inflammatory bowel disease completed an electronic survey. We measured the prevalence of exposure to AI medications and the associations with past-year alcohol use as well as binge drinking and total consumption volume in the past 3 months using multivariate regression to estimate the odds of alcohol use given AI medication exposure and perceptions of interference. RESULTS: Of 396 youth, 86.4% were on AI medications, of whom, 35.4% reported past-year alcohol use (46.3% among those who were not on AI medications). AI medication use was associated with 43% lower odds of past-year alcohol use (adjusted odds ratio: 0.57; 95% confidence interval: 0.39-0.85) and lower total consumption (β = -.43; SE = 0.11; P < .001). Perceptions of alcohol-medication interference partially mediated the relationship between AI medication exposure and past-year alcohol use (Sobel test P = .05). CONCLUSIONS: Many YCMCs reported using alcohol; however, drinking was less likely among those who were taking AI medications. Perceptions about alcohol-medication interference mediated the association between drinking and AI medication exposure, suggesting the potential salience of interventions that emphasize alcohol-related risks.
Authors: Pernille Bendtsen; Mogens Trab Damsgaard; Taisia Huckle; Sally Casswell; Emmanuel Kuntsche; Petra Arnold; Margreet E de Looze; Felix Hofmann; Anne Hublet; Bruce Simons-Morton; Tom ter Bogt; Bjørn E Holstein Journal: Addiction Date: 2014-08-05 Impact factor: 6.526
Authors: Eun Sun Jang; Sook-Hyang Jeong; Sung Ho Hwang; Hyun Young Kim; So Yeon Ahn; Jaebong Lee; Sang Hyub Lee; Young Soo Park; Jin Hyeok Hwang; Jin-Wook Kim; Nayoung Kim; Dong Ho Lee Journal: BMC Gastroenterol Date: 2012-10-18 Impact factor: 3.067
Authors: Sharon Levy; Fatma Dedeoglu; Jonathan M Gaffin; Katharine C Garvey; Elizabeth Harstad; Andrew MacGinnitie; Paul A Rufo; Qian Huang; Rosemary E Ziemnik; Lauren E Wisk; Elissa R Weitzman Journal: PLoS One Date: 2016-05-26 Impact factor: 3.240
Authors: Julie Lunstead; Elissa R Weitzman; Elizabeth Harstad; Fatma Dedeoglu; Jonathan M Gaffin; Katharine C Garvey; Andrew MacGinnitie; Paul A Rufo; Laurie Newman Fishman; Lauren E Wisk; Sharon Levy Journal: J Adolesc Health Date: 2019-06 Impact factor: 5.012
Authors: Francis Vergunst; Nicholas Chadi; Massimiliano Orri; Camille Brousseau-Paradis; Natalie Castellanos-Ryan; Jean R Séguin; Frank Vitaro; Daniel Nagin; Richard E Tremblay; Sylvana M Côté Journal: Eur Child Adolesc Psychiatry Date: 2021-05-31 Impact factor: 4.785